New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:59 EDTGBX, BRK.A, ARII, CP, TRN, CNIRegulators knew about crude-by-rail risks before crashes, NBC says
Regulators knew about issues like overloading and mislabeling that could increase the risk of shipping crude oil by rail since as early as Fall 2011, documents obtained by NBC News show. Train operators that offer crude-by-rail services include Canadian National (CNI), Canadian Pacific (CP) and BNSF, part of Berkshire Hathaway (BRK.A). Manufacturers of of rail tankcars include Trinity Industries (TRN), American Railcar (ARII), and Greenbrier (GBX). Reference Link
News For A;TRN;ARII;GBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
18:03 EDTTRNThe Federal Highway Administration updates highway guardrail review criteria
The Federal Highway Administration, FWHA, posted the following on its website: "In remarks made at the American Association of State Highway and Transportation Officials 2015 Spring Meeting in Cheyenne, Wyoming, on Friday, Federal Highway Administration Acting Administrator Gregory Nadeau announced a series of actions that will apply to the reimbursement eligibility process for states purchasing and installing guardrails, their components and other devices. FHWA is accelerating the transition to the latest crash test criteria for road safety hardware. Specifically, beginning on January 1, 2016, any proposed modification to a roadside safety device will require meeting full-scale crash test criteria outlined under AASHTO’s Manual for Assessing Safety Hardware, even if the device was previously tested and met National Cooperative Highway Research Program Report 350 criteria. “Our goal is to make our roads, bridges and highways as safe as possible, in part by accelerating the move to the newer crash test criteria,” Nadeau said. FHWA is also increasing transparency in its process for determining whether a specific device is eligible for federal reimbursement. In a letter to industry and other stakeholders, FHWA announced that it will require manufacturers and test labs to disclose all financial interests. FHWA has also recently commissioned an independent end-to-end review of the entire roadside safety hardware process from development and testing through field performance." The Fly notes that there is an ongoing probe of the safety of guardrails manufactured by Trinity Industries (TRN). Reference Link
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use